KMT2A and myeloid neoplasm: A notable contribution of OGM in characterizing myeloid neoplasms is its ability to detect cryptic chromosomal abnormalities, such as KMT2A-PTD, a cryptic intragenic alteration [17] recognized as a high-risk molecular marker in MDS according to the IPSS-M scoring system [5].